PMID- 19249315 OWN - NLM STAT- MEDLINE DCOM- 20090528 LR - 20131121 IS - 1879-0631 (Electronic) IS - 0024-3205 (Linking) VI - 84 IP - 21-22 DP - 2009 May 22 TI - Enhanced vascular contractility in alpha1-adrenergic receptor-deficient mice. PG - 713-8 LID - 10.1016/j.lfs.2009.02.020 [doi] AB - AIM: Alpha1-adrenergic receptors (alpha1-ARs) are classified into three subtypes: alpha1A-AR, alpha1B-AR, and alpha1D-AR. Triple disruption of alpha1A-AR, alpha1B-AR, and alpha1D-AR genes results in hypotension and produces no contractile response of the thoracic aorta to noradrenalin. Presently, we characterized vascular contractility against other vasoconstrictors, such as potassium, prostaglandin F2alpha (PGF(2alpha)) and 5-hydroxytryptamine (5-HT), in alpha1A-AR, alpha1B-AR, and alpha1D-AR triple knockout (alpha1-AR triple KO) mice. MAIN METHODS: The contractile responses to the stimulation with vasoconstrictors were studied using isolated thoracic aorta. KEY FINDINGS: As a result, the phasic and tonic contraction induced by a high concentration of potassium (20 mM) was enhanced in the isolated thoracic aorta of alpha1-AR triple KO mice compared with that of wild-type (WT) mice. In addition, vascular responses to PGF(2alpha) and 5-HT were also enhanced in the isolated thoracic aorta of alpha1-AR triple KO mice compared with WT mice. Similar to in vitro findings with isolated thoracic aorta, in vivo pressor responses to PGF(2alpha) were enhanced in alpha1-AR triple KO mice. Real-time reverse transcription-polymerase chain reaction analysis and western blot analysis indicate that gene expression of the 5-hydroxytryptamine 2A (5-HT(2A)) receptor was up-regulated in the thoracic aorta of alpha1-AR triple KO mice while the prostaglandin F2alpha receptor (FP) was unchanged. SIGNIFICANCE: These results suggest that loss of alpha1-ARs can lead to enhancement of vascular responsiveness to the vasoconstrictors and may imply that alpha1-ARs and the subsequent signaling regulate the vascular responsiveness to other stimulations such as depolarization, 5-HT and PGF(2alpha). FAU - Sanbe, Atsushi AU - Sanbe A AD - Department of Pharmacology, National Research Institute for Child Health and Development, 2-10-1 Okura, Setagaya-ku, Tokyo 157-8535, Japan. asanbe@nch.go.jp FAU - Tanaka, Yoshio AU - Tanaka Y FAU - Fujiwara, Yoko AU - Fujiwara Y FAU - Miyauchi, Noriko AU - Miyauchi N FAU - Mizutani, Reiko AU - Mizutani R FAU - Yamauchi, Junji AU - Yamauchi J FAU - Cotecchia, Susanna AU - Cotecchia S FAU - Koike, Katsuo AU - Koike K FAU - Tsujimoto, Gozoh AU - Tsujimoto G FAU - Tanoue, Akito AU - Tanoue A LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20090226 PL - Netherlands TA - Life Sci JT - Life sciences JID - 0375521 RN - 0 (Receptors, Adrenergic, alpha-1) RN - 0 (Vasoconstrictor Agents) RN - 333DO1RDJY (Serotonin) RN - B7IN85G1HY (Dinoprost) SB - IM MH - Animals MH - Aorta, Thoracic/drug effects MH - Blood Pressure/drug effects MH - Blotting, Western MH - Dinoprost/pharmacology MH - Dose-Response Relationship, Drug MH - Gene Expression/physiology MH - Gene Targeting MH - Heart Rate/drug effects MH - Mice MH - Mice, Inbred C57BL MH - Mice, Knockout MH - Muscle Contraction/*genetics/*physiology MH - Muscle, Smooth, Vascular/*physiology MH - Receptors, Adrenergic, alpha-1/*genetics/*physiology MH - Reverse Transcriptase Polymerase Chain Reaction MH - Serotonin/pharmacology MH - Vasoconstrictor Agents/pharmacology EDAT- 2009/03/03 09:00 MHDA- 2009/05/29 09:00 CRDT- 2009/03/03 09:00 PHST- 2008/09/01 00:00 [received] PHST- 2009/01/28 00:00 [revised] PHST- 2009/02/12 00:00 [accepted] PHST- 2009/03/03 09:00 [entrez] PHST- 2009/03/03 09:00 [pubmed] PHST- 2009/05/29 09:00 [medline] AID - S0024-3205(09)00093-9 [pii] AID - 10.1016/j.lfs.2009.02.020 [doi] PST - ppublish SO - Life Sci. 2009 May 22;84(21-22):713-8. doi: 10.1016/j.lfs.2009.02.020. Epub 2009 Feb 26.